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Introduction. Metabolic syndrome (MetS) is an assemblage of interconnected cardiovascular risk factors that are prevalent among
children and adolescents in high-income countries (HICs). Despite the presence of several studies on the issue, the study findings
are incongruent due to the absence of a gold standard diagnostic method of MetS in children. Thus, the findings of the original
studies are inconclusive for policy makers and other stakeholders. This systematic review and meta-analysis is aimed at giving
conclusive evidence about MetS among children and adolescents in HICs. Methods. We conducted searches using electronic
databases (PubMed, Scopus, Web of Science, CINAHL (EBSCOhost), EMBASE (Elsevier), and Medline (EBSCOhost)) and
other sources (Google Scholar and Google) up to September 2020. Observational studies reporting the prevalence of MetS were
eligible in this study. The pooled estimates were computed in fixed and random effect models using six diagnostic methods
(IDF, ATP III, de Ferranti et al., WHO, Weiss et al., and Cruz and Goran). Publication bias was verified using funnel plots and
Egger’s regression tests. Subgroup and sensitivity analysis were performed in case of higher heterogeneities among the included
studies. Result. In this study, 77 studies with a total population of 125,445 children and adolescents were used in the final
analysis. Metabolic syndrome among the overweight and obese population was computed from 28 studies with the pooled
prevalence of 25.25%, 24.47%, 39.41%, 29.52%, and 33.36% in IDF, ATP III, de Ferranti et al., WHO, and Weiss et al. criteria,
respectively. Likewise, 49 studies were eligible to compute the pooled prevalence of MetS in the general population of children
and adolescents. Hence, MetS was found in 3.70% (IDF), 5.40% (ATP III), 14.78% (de Ferranti et al.), 3.90% (WHO), and,
4.66% (Cruz and Goran) of study participants. Regarding the components of MetS, abdominal obesity in the overweight and
obese population, and low HDL-C in the general population were the most common components. Besides, the prevalence of
Mets among males was higher than females. Conclusion. This study demonstrates that MetS among children and adolescents is
undoubtedly high in HICs. The prevalence of MetS is higher among males than females. Community-based social and
behavioral change communications need to be designed to promote healthy eating behaviors and physical activities. Prospective
cohort studies could also help to explore all possible risk factors of MetS and to design specific interventions accordingly.
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1. Introduction
Metabolic syndrome (MetS) is an assemblage of intercon-
nected cardiovascular risk factors of metabolic origin [1].
Elevated triglycerides (TG), altered glucose metabolism,
reduced high-density lipoprotein cholesterol (HDL-C), and
elevated blood pressure (BP) and adiposity are the main risk
factors [2]. It is primarily caused by insulin resistance due to
abnormal cellular metabolism, leading to diabetes mellitus,
increased uric acid level, hepatic steatosis, polycystic ovary
syndrome, and obstructive sleep apnea [3–8].
The definition of MetS in children and adolescents
remains unclear due to the absence of gold standard diagnos-
tic criteria of MetS for the pediatric population [9]. Some of
the diagnostic criteria used by studies include the Interna-
tional Diabetes Federation (IDF) criteria [10], the World
Health Organization (WHO) criteria [11], the National Cho-
lesterol Education Program Adult Treatment Panel III
(NCEP-ATP III) criteria modified for age [12], the de Fer-
ranti et al. criteria [13], the Weiss et al. criteria [14], and
the Cruz and Goran criteria [15].
Globally, an estimated 3.3% with a range of 0.2% to
38.9% of children and adolescents were expected to live with
MetS. The prevalence was considerably higher in the over-
weight (11.9%) and obese (29.2%) population [9, 16, 17].
Likewise, the prevalence of MetS is remarkably higher in
high-income countries (HICs) due to increasing trends of
childhood obesity rates [18]. The rise in obesity in the past
four decades could be primarily associated with related life-
style factors such as routine consumption of fructose in the
form of soft drinks, juice, and baked goods [19–22]. Thus,
obesity increased MetS in children and adolescents from
6% to 39% [23].
Metabolic syndrome has been a global pandemic affect-
ing children and adults [24]. The burden is significantly
higher in the developed world posing a high economic bur-
den on the health care system [25]. Cardiovascular and other
metabolic complications are also common consequences of
MetS in children [26]. In addition, MetS also negatively
impacts the mental status and over all cognitive performance
of children and adolescents [27]. In spite of the fact that mul-
tiple treatment strategies were designed and implemented,
the prevalence of MetS remained high in most high-income
countries with a remarkable variation among countries [28,
29]. Primary studies substantiated this by showing that the
prevalence of MetS in the general population ranged from
0.4% [30] to 24% [31]. Similarly, the prevalence in the obese
population ranged from 6% [32] to as high as 55.8% [33].
There is also considerable variation among the diagnostic
methods of MetS in the pediatric population [34].
Though comprehensive systematic reviews and meta-
analyses are vital for evidence-based decision making, they
are scant in HICs where the burden of MetS is undoubtedly
higher. Hence, this systematic review and meta-analysis is
aimed at determining the pooled prevalence of MetS among
children and adolescents in HICs and at giving conclusive
evidence about its burden in these countries. The findings
will be vital for policy makers and program planners in craft-
ing preventive and treatment measures. The current findings
will be supplementary for assessing the progress of sustain-
able development goals, specifically, ending all forms of mal-
nutrition by 2030 [35]. In addition, the findings of this study
will have a pivotal implication to conduct original studies on
a multitude of factors related to high-burden MetS among
the pediatric population.
2. Methods
2.1. Data Sources and Eligibility Criteria. Studies performed
in HICs with the aim of identifying MetS among children
and adolescents were included in this systematic review and
meta-analysis. The eligibility of the studies was verified prior
to inclusion to this study using study area, study setups, title,
abstract, and full texts. The Preferred Reporting Items for
Systematic Reviews and Meta-analysis (PRISMA) guideline
[36] was followed in the write-up process of the whole docu-
ment. We explored national surveys and published and
unpublished studies conducted in English. The reference lists
of selected articles were also cross-checked for additional
articles that were not found using search strings. Studies con-
ducted until September 2020 were searched. Finally, observa-
tional studies reporting the prevalence of MetS among
children and adolescents conducted both in clinical and
community-based setups were included.
Conversely, studies with incomplete or unclear diagnos-
tic methods and studies without full texts were excluded.
We communicated with the corresponding authors using
email before making the decision to exclude studies without
full texts. Letters to editors, conference proceedings, and
qualitative studies were also excluded. The EndNote X8 ref-
erence manager was used to manage the retrieved articles.
2.2. Search Strategies and Study Selection Process. A compre-
hensive search was performed by three investigators (ZWB,
ZT, and TW), independently. Literature searches were con-
ducted for studies published up to September 2020 using
databases such as PubMed, Scopus, Web of Science,
CINAHL (EBSCOhost), EMBASE (Elsevier), and Medline
(EBSCOhost) as well as other sources (Google Scholar and
Google). The following key terms were used for searching:
(a) population (children, child, school age, and adolescent),
(b) exposure (associated factors and risk factors), (c) outcome
(metabolic syndrome, MetS, components of metabolic
syndrome, and cardiovascular risk factors), (d) study
design (cohort studies, cross-sectional studies, epidemiol-
ogy, observational studies, and national health surveys),
(e) study setting (school, community-based surveys, and
health institutions), and (f) location (high-income countries,
HICs, developed countries, and names of high-income coun-
tries). The Boolean search operators “OR” and “AND” were
used during the searching process, and the appropriateness
of the key terms were checked before conducting the search
in each of the explored databases. An example of a search
string in PubMed is shown in Table 1.
2.3. Data Extraction Process. Data extraction was done by
three authors (ZWB, AA, and TW) independently using a
standardized data extraction checklist. The extraction
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checklist was prepared using Microsoft Excel 2016. The
checklist included the name of the author(s), publication
year, study country, sample size, age of the study population,
gender distribution of MetS, prevalence of MetS with differ-
ent diagnostic methods, and components. Discrepancies
between the three investigators in the extraction process were
resolved through discussion and consensus. The other author
(AA) cross-checked the studies and solved inconsistencies
accordingly.
2.4. Quality Assessment of Studies. The qualities of the
included studies were assessed by two authors (ZWB and
AA), independently. Joanna Briggs Institute (JBI) Critical
Appraisal Checklist for Observational Studies was used for
quality assessment [37]. The tool has four options (yes, no,
unknown, and not applicable). One is given for yes, and zero
was given for the other options. The scores were added up
and changed to percentages. The minimum score was zero,
and the maximum score was eight. Studies with >50% quality
scores were included in this meta-analysis (Additional file 1).
The interrater agreement was computed by an author (ZT)
after the critical appraisals and prior to the final decision of
inclusion. The interrater agreement was computed using
Cohen’s kappa coefficient (κ). The findings revealed that
there was substantial agreement [38] between the two raters
(κ = 0:784; p ≤ 0:001).
2.5. Summary Measures. Metabolic syndrome among chil-
dren and adolescents in HICs with different diagnostic
methods is the primary outcome of this study. The pooled
prevalence of MetS was calculated in the general population
and overweight and obese adolescents, separately. The
general population included underweight, normal weight,
overweight, and obese children and adolescents. The other
outcomes were components of MetS and the pooled preva-
lence of MetS among the male and female population. The
recent list of HICs was obtained from the World Bank data-
base [39]. The prevalence was calculated by dividing the total
number of events (MetS) to the total sample size and multi-
plying it by 100. The binomial distribution formula was used
to compute the standard error for each original study. The
pooled estimates were computed from prevalence and stan-
dard error of prevalence using the “metan” commands in
the STATA (version 15) software. The pooled estimates were
presented with their 95% CIs. The effect sizes were preva-
lence of MetS in HICs and the respective components.
Regarding the diagnostic criteria, the pooled estimates of
MetS in HICs were computed using six diagnostic methods.
The respective definitions are presented as follows. In the
IDF diagnostic criteria, MetS is diagnosed if children aged
between 10 and 16 years have central adiposity (≥90th cen-
tile) and two of the following: triglycerides ðTGÞ ≥ 150mg/
dl, HDL − C < 40mg/dl, systolic blood pressure ðBPÞ ≥ 130
mmHg or diastolic BP ≥ 85mmHg, and fasting plasma
glucose ðFGÞ ≥ 100mg/dl or previously diagnosed type 2 dia-
betes [10]. Based on the WHO criteria, MetS is diagnosed
when three or more of the following criteria are met: body
mass index ðBMIÞ > 95th percentile, hyperinsulinemia or
impaired fasting glucose or impaired glucose tolerance, BP
> 95th percentile, TG > 105/136mg/dl (1.2/1.5mmol/l) for
children aged <10 and >10 years, respectively, and HDL −
C < 35mg/dl (0.9mmol/l) [11]. Based on the NCEP-ATP
Table 1: Search string used for searching articles from PubMed.
Population (Children) OR (school children)) OR (“Child”[Mesh])) OR (“Adolescent”[Mesh])




[Subheading]) AND (“Metabolic Syndrome”[Mesh])) AND (“Child”[Mesh])) OR (children)) AND
(“Adolescent”[Mesh])) AND (“Developed Countries”[Mesh])) OR (high income countries)) OR (“Andorra”[Mesh]))
OR (“Antigua and Barbuda”[Mesh])) OR (“Aruba”[Mesh])) OR (“Australia”[Mesh])) OR (“Austria”[Mesh])) OR
(“Bahamas”[Mesh])) OR (“Bahrain”[Mesh])) OR (“Barbados”[Mesh])) OR (“Belgium”[Mesh])) OR
(“Bermuda”[Mesh])) OR (“British Virgin Islands”[Mesh])) OR (“Brunei”[Mesh])) OR (“Canada”[Mesh])) OR (“West
Indies”[Mesh])) OR (“Channel Islands”[Mesh])) OR (“Chile”[Mesh])) OR (“Croatia”[Mesh])) OR (“Curacao”[Mesh]))
OR (“Cyprus”[Mesh])) OR (“Czech Republic”[Mesh])) OR (“Denmark”[Mesh])) OR (“Estonia”[Mesh])) OR
(“Finland”[Mesh])) OR (“France”[Mesh])) OR (“Polynesia”[Mesh])) OR (“Germany”[Mesh])) OR
(“Gibraltar”[Mesh])) OR (“Greece”[Mesh])) OR (“Greenland”[Mesh])) OR (“Guam”[Mesh])) OR (“Hong
Kong”[Mesh])) OR (“Hungary”[Mesh])) OR (“Iceland”[Mesh])) OR (“Ireland”[Mesh])) OR (“Israel”[Mesh])) OR
(“Italy”[Mesh])) OR (“Japan”[Mesh])) OR (“Republic of Korea”[Mesh])) OR (“Kuwait”[Mesh])) OR (“Latvia”[Mesh]))
OR (“Liechtenstein”[Mesh])) OR (“Lithuania”[Mesh])) OR (“Luxembourg”[Mesh])) OR (“Macau”[Mesh])) OR
(“Malta”[Mesh])) OR (“Mauritius”[Mesh])) OR (“Monaco”[Mesh])) OR (“Micronesia”[Mesh])) OR
(“Netherlands”[Mesh])) OR (“New Caledonia”[Mesh])) OR (“New Zealand”[Mesh])) OR (“Norway”[Mesh])) OR
(“Oman”[Mesh])) OR (“Palau”[Mesh])) OR (“Panama”[Mesh])) OR (“Poland”[Mesh])) OR (“Portugal”[Mesh])) OR
(“Puerto Rico”[Mesh])) OR (“Romania”[Mesh])) OR (“Qatar”[Mesh])) OR (“San Marino”[Mesh])) OR (“Saudi
Arabia”[Mesh])) OR (“Seychelles”[Mesh])) OR (“Singapore”[Mesh])) OR (“Slovakia”[Mesh])) OR (“Slovenia”[Mesh]))
OR (“Spain”[Mesh])) OR (“Saint Kitts and Nevis”[Mesh])) OR (“Sint Maarten”[Mesh])) OR (“Sweden”[Mesh])) OR
(“Switzerland”[Mesh])) OR (“Taiwan”[Mesh])) OR (“Trinidad and Tobago”[Mesh])) OR (“United Arab
Emirates”[Mesh])) OR (“United Kingdom”[Mesh])) OR (“United States”[Mesh])) OR (“Uruguay”[Mesh])) OR
(“United States Virgin Islands”[Mesh]) Filters: Abstract,Observational Study, in the last 10 years, Humans, English,
Child: 6-12 years, Adolescent: 13-18 years
Filters Filters: free full text, observational study, in the last 10 years, humans, English, child: 6-12 years, adolescent: 13-18 years
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III criteria modified for age, MetS is diagnosed when three of
the following criteria are met:TG ≥ 110mg/dl, HDL − C ≤
40mg/dl, systolic BP or diastolic BP ≥ 90th percentile, waist
circumference ≥ 90th percentile for age and gender, and FG
≥ 110mg/dl [12]. According to de Ferranti et al., MetS is a
clustering of at least three of the following criteria: FG ≥
110mg/dl; HDL − C ≤ 50mg/dl (except in boys aged 15 to
19 years in whom the cut-off point is 45mg/dl); TG ≥ 100
mg/dl; systolic BP > 90th percentile for gender, age, and
height; and WC> 75th percentile for age and gender [13].
According to Cruz and Goran, MetS is defined as the pres-
ence of at least three of the following abnormalities: abdom-
inal obesity (WC> 90th percentile for age and gender),
hypertriglyceridemia (TG > 90th percentile for age and gen-
der), low HDL-C (HDL − C > 10th percentile for age and
gender), hypertension (systolic or diastolic blood pressure >
90th percentile adjusted for height, age, and gender), and
impaired glucose tolerance [15]. Furthermore, Weiss et al.
diagnosed MetS when three or more of the following are
obtained: obesity (BMIZ score ≥ 2:0), fasting glycemia (gly-
cemia at oral glucose tolerance test of 140-200mg/dl), ele-
vated BP (BP > 95th centile), low HDL-C (HDL − C < 5th
centile), and high TG (TG > 95th centile) [14].
2.6. Statistical Methods and Analysis. In this meta-analysis,
STATA version 15 (STATA Corporation, College Station
Texas) software was used to calculate the pooled estimates.
The pooled estimates were computed using both random
and fixed effect models. In the presence of high heterogeneity
among studies, the pooled estimates were computed using
random effect models and were weighted using the inverse
variance method. Subgroup analyses were performed using
different parameters. The pooled estimates in the general
and overweight and obese population were presented sepa-
rately. For the subgroup analysis, data were extracted based
on study continent, study country, and gender of study sub-
jects. The appropriateness of each datum was verified before
the analyses. Forest plots, summery tables, and texts were
used to present the findings of this study.
2.7. Publication Bias and Heterogeneity. Publication bias was
assessed using the funnel plot and Egger’s regression test at a
5% significant level [40]. Heterogeneity among included
studies was explored using the forest plot, the I2 test, and
the Cochrane Q statistics [41]. The I2 values of 25%, 50%,
and 75% were interpreted as low, medium, and high hetero-
geneity, respectively [42]. In the present meta-analysis,
significant heterogeneity was considered when the I2 value
was ≥50%, with a p value < 0.05. The possible sources of
significant heterogeneity were addressed through subgroup
and sensitivity analyses.
3. Results
3.1. Selection of Eligible Studies.We found 5514 studies in our
initial search from reputable databases and grey literature
sources. Primarily, 765 studies were duplicated files. A total
of 4749 studies were screened using titles and abstracts, and
4648 were removed due to the fact that most of the results
were unrelated to our objective. Finally, the full texts of 101
studies were assessed for eligibility criteria. Of 101 studies,
24 were excluded due to inconsistency of results [43–59],
incompleteness of results [60–64], and publications not in
English language [65, 66]. Seventy seven studies were
included in the current systematic review and meta-analysis,
of which 49 [13, 30, 31, 67–112] were used in computing the
pooled prevalence of MetS in the general population and 29
[14, 15, 32, 33, 113–136] were used for estimating the pooled
prevalence of MetS in overweight and obese study subjects
(Figure 1).
3.2. Characteristics of the Included Studies. All studies
included in this study were cross-sectional studies. Out of
the total 77 studies, 49 studies were conducted among the
general population of children and adolescents [13, 30, 31,
67–112]. The remaining 28 studies were performed in the
overweight and obese population [14, 15, 32, 33, 113–136].
In this review, 125,445 study participants were included, of
which 113,742 were from the general population and
11,703 were from the overweight and obese population. In
the overweight and obese population, the sample size ranged
from 97 [136] to 1241 [119] children. Likewise, the sample
size in the general population ranged from 234 [111] to
12,147 [30]. The age range of study subjects in both groups
was between 2 and 19 years. Regarding geographic distribu-
tion of studies, 34 studies were conducted in Europe, while
23, 16, 2, and 2 studies were conducted in Asia, USA, Canada,
and Latin America, respectively. The quality of articles was
also assessed using the JBI checklists. Thus, 48 studies were
classified under medium quality, and 29 studies had high
quality (Tables 2 and 3).
3.3. Metabolic Syndrome among Overweight and Obese
Children and Adolescents. The pooled prevalence of MetS
was estimated using five diagnostic methods (IDF, ATP III,
de Ferranti, Weiss, and WHO). In the IDF diagnostic
method, thirteen studies [32, 33, 119, 126, 128–132, 134–
136] were used to compute the pooled prevalence of MetS
(25.25%; 95% CI: 19.31, 31.19; I2 = 97:5%; p ≤ 0:001).
Regarding the components, abdominal obesity was found to
be the most common component (65.62%; 95% CI: 47.09,
84.15; I2 = 99:4%; p ≤ 0:001), and high FG level was the least
common component (7.64%; 95% CI: 4.81, 10.46; I2 = 97:3%;
p ≤ 0:001). According to the ATP III method, the pooled
prevalence of MetS was computed using 15 eligible studies
[32, 113, 115, 116, 118–121, 123–127, 129, 133]. One quarter
(24.47%; 95% CI: 19.87, 29.08; I2 = 94:9%; p ≤ 0:001) of study
subjects were diagnosed with MetS. Regarding the compo-
nents of MetS, abdominal obesity was the most common
component (79.8%; 95% CI: 67.39, 92.23; I2 = 99:5%; p ≤
0:001), and high FG level was the most infrequent compo-
nent (7.77%; 95% CI: 5.53, 10.02; I2 = 96:3; p ≤ 0:001). The
highest pooled prevalence of MetS (39.41%; 95% CI: 34.62,
44.22; I2 = 78:3%; p ≤ 0:01) among the overweight and obese
population was recorded in the de Ferranti diagnostic cri-
teria, using three eligible studies [32, 115, 119]. Three quar-
ters (75.72%; 95% CI: 67.29, 84.15; I2 = 96%; p ≤ 0:001) of
children and adolescents were found to have abdominal
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obesity and only 1.61% (0.34, 2.88, 84.1%; p ≤ 0:01) of them
had high FG level. According to the WHO diagnostic cri-
teria, MetS was found in 29.52% (95%: 16.69, 42.35; I2 =
99:1%; p ≤ 0:001) of the study population and it was com-
puted from seven eligible studies [32, 114, 117, 119, 121,
122, 129]. In this diagnostic criteria, abdominal obesity
(73.41%; 95% CI: 62.73, 84.09; I2 = 99:8%; p ≤ 0:001) was
the frequent component, whereas high FG was the infre-
quent one (11.12%; 95% CI: 3.67, 18. 57; I2 = 98:7; p ≤
0:001). Only three studies [14, 15, 32] were used to compute
the pooled prevalence of MetS (33.36%; 95% CI: 25.06,
41.65; I2 = 89:9%; p ≤ 0:001) in the Weiss diagnostic criteria.
Similar to the other diagnostic methods, abdominal obesity
(71.48%; 95%: 53.87, 89.10; I2 = 93:8%; p ≤ 0:001) and high
FG level (15.53%; 95% CI: -7.01, 38.07; I2 = 99:1%; p ≤
0:001) were the most and least frequent components, respec-
tively, in the Weiss criteria.
The pooled prevalence of MetS was also estimated among
males and females. The prevalence of MetS was relatively
higher in males (26.62%) than in females (20.18%) in the
IDF method. However, the pooled prevalence was nearly
similar among males (24.75%) and females (24.97%) in
accordance with the ATP III diagnostic method (Figure 2
and Table 4).
3.4. Metabolic Syndrome among the General Population of
Children and Adolescents. In the general population of chil-
dren and adolescents, the pooled prevalence of MetS was
computed using the IDF, ATP III, de Ferranti, Cruz and
Goran, and WHO diagnostic criteria. The pooled prevalence
of MetS was estimated to be 3.70% (95% CI: 2.96, 4.44; I2 =
97:5%; p ≤ 0:001) with the IDF diagnostic criteria, which
was computed from 23 original studies [30, 73, 74, 77, 79,
81–83, 85, 87, 88, 93, 94, 98–101, 103, 104, 106, 108, 112].
Regarding the components of MetS, low HDL-C was the
most prevalent component (23.41%; 95% CI: 14.71, 32.11;
I2 = 99:8%; p ≤ 0:001), whereas high TG level was the least
prevalent component (7.10%; 95% CI: 4.72, 9.48; I2 =
98:4%; p ≤ 0:001). Coming to the ATP III diagnostic
method, the pooled prevalence of MetS was found to be
6.08% (95% CI: 5.08, 7.07; I2 = 98:2%; p ≤ 0:001), and it
was estimated from 33 studies [30, 31, 67–72, 74, 76–80,
83, 84, 86, 89–92, 95–98, 100–102, 105, 107–109, 111].
In this diagnostic method, elevated BP was the most common
component (21.43%; 95% CI: 16.60, 26.25; I2 = 99:6%; p ≤
0:001) and high FG level (7.16%; 95% CI: 5.22, 9.11; I2 =
99:4%; p ≤ 0:001) was the least common component. The
highest (14.78%; 95% CI: 11.02, 18.54; I2 = 96:5; p ≤ 0:001)
pooled prevalence of MetS was recorded in the de Ferranti
diagnostic criteria, which was computed from four eligible
studies [13, 31, 78, 106]. In accordance with the Cruz and
Goran diagnostic criteria, the pooled prevalence of MetS
was computed from two studies [75, 78], and it was found
to be 4.66% (95% CI: 3.29, 6.03; I2 = 76:6%; p ≤ 0:01). Ele-
vated BP was the most prevalent component (27.50%; 95%
CI: 12.12, 42.89; I2 = 99:0; p ≤ 0:001) of MetS, and abdominal
obesity was the most infrequent component (10.06%; 95%
CI: 7.12, 13.00; I2 = 89:6%; p ≤ 0:01). Besides, the pooled
prevalence of MetS was estimated using the WHO diagnostic
method from three studies [68, 79, 110]. Accordingly, 3.90%
(95% CI: 0.60, 7.20; I2 = 97:2%; p ≤ 0:001) of the study sub-
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Figure 2: The pooled prevalence of MetS among overweight and obese children and adolescents in high-income countries, 2020.
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(14.42%; 95% CI: 12.82, 16.02) was abdominal obesity, and
the lowest one was high FG level (1.63%; 95% CI: 1.06,
2.21), with no heterogeneity among the included studies.
The gender-based distribution of MetS in the general
population was also estimated in all diagnostic methods.
The pooled prevalence of MetS among males was higher than
females in the IDF (3.80%, 2.37%), ATP III (6.61%, 4.65%),
and Cruz and Goran (5.53%, 4.22%) diagnostic methods.
On the contrary, the pooled prevalence of MetS was lower
among males than among females in the de Ferrranti
(16.49%, 16.76%) and WHO (2.66%, 3.03%) diagnostic cri-
teria (Figure 3 and Table 5).
3.5. Subgroup Analysis of the Pooled Prevalence of MetS in the
General Population. The subgroup analyses were performed
for the two diagnostic methods (IDF and ATP III) using con-
tinents where the original studies were performed. In the IDF
diagnostic method, the pooled prevalence of MetS was esti-
mated in three continents (North America, Asia, and
Europe). Accordingly, the highest prevalence was recorded
Table 4: Pooled prevalence of MetS in overweight and obese children and adolescents in HICs.
Variables Characteristics # of studies Pooled prevalence (95% CI) Heterogeneity (I2 (%), p value) Model
Diagnostic criteria
IDF 13 25.25 (19.31, 31.19) 97.5, p ≤ 0:001 REM
ATP III 15 24.47 (19.87, 29.08) 94.9, p ≤ 0:001 REM
de Ferranti 3 39.41 (34.62, 44.22) 78.3, p = 0:010 REM
WHO 7 29.52 (16.69, 42.35) 99.1, p ≤ 0:001 REM
Weiss 3 33.36 (25.06, 41.65) 89.9, p ≤ 0:001 REM
Components of MetS (IDF)
Abdominal obesity 5 65.62 (47.09, 84.15) 99.4, p ≤ 0:001 REM
Low HDL-C 9 34.77 (26.63, 42.90) 97.5, p ≤ 0:001 REM
High TG 10 24.11 (10.61, 37.62) 99.5, p ≤ 0:001 REM
High FG 9 7.64 (4.81, 10.46) 97.3, p ≤ 0:001 REM
Elevated BP 8 34.80 (22.08, 47.51) 98.9, p ≤ 0:001 REM
Components of MetS (ATP III)
Abdominal obesity 10 79.81 (67.39, 92.23) 99.5, p ≤ 0:001 REM
Low HDL-C 13 29.94 (20.83, 39.05) 98.3, p ≤ 0:001 REM
High TG 14 28.43 (16.72, 40.13) 99.2, p ≤ 0:001 REM
High FG 13 7.77 (5.53, 10.02) 96.3, p ≤ 0:001 REM
Elevated BP 13 30.38 (21.72, 39.04) 98.5, p ≤ 0:001 REM
Components of MetS (de Ferranti)
Abdominal obesity 2 75.72 (67.29, 84.15) 96.0, p ≤ 0:001 REM
Low HDL-C 2 51.24 (45.85, 56.63) 86.5, p = 0:007 REM
High TG 2 47.39 (38.38, 56.41) 95.2, p ≤ 0:001 REM
High FG 2 1.61 (0.34, 2.88) 84.1, p = 0:012 REM
Elevated BP 2 35.04 (29.06, 41.02) 90.1, p = 0:002 REM
Components of MetS (WHO)
Abdominal obesity 6 73.41 (62.73, 84.09) 99.8, p ≤ 0:001 REM
Low HDL-C 4 17.91 (12.30, 23.69) 94.5, p ≤ 0:001 REM
High TG 6 31.82 (10.02, 53.63) 99.7, p ≤ 0:001 REM
High FG 6 11.12 (3.67, 18. 57) 98.7, p ≤ 0:001 REM
Elevated BP 5 24.38 (11.79, 36.98) 98.8, p ≤ 0:001 REM
Components of MetS (Weiss)
Abdominal obesity 2 71.48 (53.87, 89.10) 93.8, p ≤ 0:001 REM
Low HDL-C 2 41.48 (-7.16, 90.83) 99.3, p ≤ 0:001 REM
High TG 2 34.89 (18.25, 51.53) 94.0, p ≤ 0:001 REM
High FG 2 15.53 (-7.01, 38.07) 99.1, p ≤ 0:001 REM
Elevated BP 2 23.07 (19.05, 27.10) 31.6, p = 0:227 REM
Gender (IDF)
Male 4 26.62 (14.48, 38.75) 97.3, p ≤ 0:001 REM
Female 4 20.18 (9.02, 31.14) 94.5, p ≤ 0:001 REM
Gender (ATP III)
Male 5 24.75 (13.42, 36.07) 93.8, p ≤ 0:001 REM
Female 5 24.97 (16.89, 33.06) 85.2, p ≤ 0:001 REM
REM: random effect model.
12 BioMed Research International
in Asia, where 4.72% (95% CI: 3.40, 6.04; I2 = 96:7%; p ≤
0:001) of the children and adolescents were found to have
MetS. Likewise, the pooled prevalence of MetS in North
America and that in Europe were 3.95% (95% CI: 1.95,
5.96; I2 = 90:9%; p ≤ 0:001) and 2.54% (95% CI: 1.64, 3.44;
I2 = 97%; p ≤ 0:001), respectively (Figure 4).
Similarly, the pooled prevalence of MetS was computed
for three eligible continents (North America, Asia, and
Europe) using the ATP III diagnostic criteria. Thus, 6.79%
(95% CI: 5.40, 8.18; I2 = 96:9%; p ≤ 0:001) of the study sub-
jects in North America were diagnosed to have MetS. In Asia,
the pooled prevalence of MetS was 6.32% (95% CI: 5.05, 7.58;
I2 = 94:9; p ≤ 0:001), and it was 3.84% (95% CI: 2.83, 4.85;
I2 = 94:9%; p ≤ 0:001) in Europe (Figure 4).
The heterogeneity among the included studies remained
significant after subgroup analysis. Hence, the possible
sources of heterogeneity were further explored for the two
diagnostic methods (IDF and ATP III). Thus, the funnel plots
Study
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Figure 3: The pooled prevalence of MetS among the general population of children and adolescents in high-income countries, 2020.
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for both diagnostic criteria were presented (Figure 5). The
asymmetry of the plots was objectively verified by Egger’s
regression test, and there was publication bias among the
articles included in computing the pooled prevalence of MetS
in the IDF (p ≤ 0:001) and ATP III (p ≤ 0:001) diagnostic
methods. Moreover, sensitivity analyses were performed for
both diagnostic methods. This was done to evaluate if the
pooled estimates were altered by the exclusion of any single
study. However, none of the studies had significant effects
in the pooled estimates (Figure 6).
Finally, the Duval and Tweedie trim and fill analysis, a
nonparametric method of accounting for publication bias
in meta-analysis, was employed to estimate the pooled prev-
alence. This was done to estimate the number and outcomes
Table 5: The pooled prevalence of MetS and components in the general population in HICs.




(I2 (%), p value)
Model
Diagnostic criteria
IDF 23 3.70 (2.96, 4.44) 97.5, p ≤ 0:001 REM
ATP III 33 6.08 (5.08, 7.07) 98.2, p ≤ 0:001 REM
de Ferranti 4 14.78 (11.02, 18.54) 96.5, p ≤ 0:001 REM
WHO 3 3.90 (0.60, 7.20) 97.2, p ≤ 0:001 REM
Cruz and Goran 2 4.66 (3.29, 6.03) 76.6, p = 0:039 REM
Gender distribution of MetS (IDF)
Male 19 3.80 (2.90, 4.70) 96.1, p ≤ 0:001 REM
Female 20 2.37 (1.77, 2.96) 92.3, p ≤ 0:001 REM
Gender distribution of MetS (ATP III)
Male 27 6.61 (5.10, 8.13) 98.4, p ≤ 0:001 REM
Female 28 4.65 (3.75, 5.54) 98.6, p ≤ 0:001 REM
Gender distribution of MetS (de F.)
Male 3 16.49 (12.80, 20.17) 88.4, p ≤ 0:001 REM
Female 3 16.76 (12.11, 21.41) 92.4, p ≤ 0:001 REM
Gender distribution of MetS (WHO)
Male 2 2.66 (0.61, 4.72) 86.0, p = 0:008 REM
Female 2 3.03 (-0.11, 6.16) 93.0, p ≤ 0:001 REM
Gender distribution of MetS (Cruz and Goran)
Male 2 5.53 (3.09, 7.98) 82.8, p = 0:016 REM
Female 2 4.22 (3.27, 5.17) 21.1, p = 0:260 FEM
Components MetS (IDF)
Abdominal obesity 14 16.13 (11.47, 20.79) 99.3, p ≤ 0:001 REM
Low HDL-C 14 23.41 (14.71, 32.11) 99.8, p ≤ 0:001 REM
High TG 13 7.10 (4.72, 9.48) 98.4, p ≤ 0:001 REM
High FG 13 10.62 (6.64, 14.59) 99.0, p ≤ 0:001 REM
Elevated BP 12 14.56 (10.52, 18.59) 99.2, p ≤ 0:001 REM
Components MetS (ATP III)
Abdominal obesity 21 16.28 (13.03, 19.53) 99.1 p ≤ 0:001 REM
Low HDL-C 21 17.45 (14.43, 20.47) 98.9, p ≤ 0:001 REM
High TG 21 19.05 (14.84, 23.26) 99.4, p ≤ 0:001 REM
High FG 21 7.16 (5.22, 9.11) 99.4, p ≤ 0:001 REM
Elevated BP 21 21.43 (16.60, 26.25) 99.6, p ≤ 0:001 REM
Components MetS (WHO)
Abdominal obesity 2 14.42 (12.82, 16.02) 0.00, p = 0:846 FEM
Low HDL-C 2 3.78 (1.43, 6.13) 82.8, p = 0:016 REM
High TG 2 5.82 (3.46, 8.19) 64.2, p = 0:094 REM
High FG 2 1.63 (1.06, 2.21) 0.00, p = 0:672 FEM
Elevated BP 2 3.49 (0.65, 6.34) 89.7, p = 0:002 REM
Components MetS (Cruz and Goran)
Abdominal obesity 2 10.06 (7.12, 13.00) 89.6, p = 0:002 REM
Low HDL-C 2 10.47 (7.93, 13.02) 85.3, p = 0:009 REM
High TG 2 11.15 (10.25, 12.06) 0.00, p = 0:383 FEM
High FG 2 16.65 (-5.99, 39.28) 99.8, p ≤ 0:001 REM
Elevated BP 2 27.50 (12.12, 42.89) 99.0, p ≤ 0:001 REM
∗Others: underweight and normal weight; REM: random effect model; FM: fixed effect model.
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Figure 4: Pooled prevalence of MetS based on continent in two diagnostic methods (IDF and ATP III).
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of missing studies, and adjust the meta-analysis to incorpo-
rate the theoretical missing studies. Nevertheless, the pooled
prevalence of MetS remained the same (3.70%) using the IDF
criteria. However, the pooled prevalence of MetS among the
general population of children and adolescents was reduced
to 5.40% (95% CI: 4.47, 6.32) in the ATP III diagnostic
criteria.
Eventually, the trend of MetS in the general population of
children and adolescents in HICs was plotted in a scatter plot
based on the prevalence of cases with publication year (2003
to 2020). The trend line implied that there is an increasing
trend of cases in three diagnostic methods (IDF, ATP III,
and de Ferranti) (Figure 7).
4. Discussion
This is a comprehensive systematic review andmeta-analysis,
determining the prevalence of metabolic syndrome among
children and adolescents in high-income countries. The
pooled prevalence of MetS was computed using six diagnos-
tic methods: IDF, ATP III, de Ferranti et al., WHO, Weiss
et al., and Cruz and Goran. In the current meta-analysis, 77
studies with a total of 125,445 study participants were
included. Of the total studies, 49 were conducted among
the general population of study subjects, and 28 were con-
ducted among overweight and obese population.
This study revealed that the prevalence of MetS among
overweight and obese study participants is considerably
higher than its prevalence in the general population. The
pooled prevalence of MetS in the overweight and obese chil-
dren and adolescents is as follows: IDF = 25:25%; ATP III =
24:47%; de Ferranti et al: = 39:41%; WHO= 29:52%; and
Weiss et al: = 33:36%. Likewise, the pooled prevalence in the
general population was 3.70%, 6.08%, 14.78%, 3.90%, 4.66%
with the IDF, ATP III, de Ferranti, WHO, and Cruz and
Goran diagnostic criteria, respectively. The prevalence in
the general population is comparable with findings of a sys-
tematic review from Iran, where the prevalence of MetS was
0-8%, 3-16%, and 0-22% in the IDF, ATP III, and de Ferranti
criteria, respectively [137]. But, Iranian findings are remark-
ably lower than the current pooled prevalence of MetS
among the overweight and obese population. A possible rea-
son for this disparity may be explained by the fact that over-
weight and obese children are at greater risk of developing
metabolic syndrome as compared to children with normal
weight [19]. Furthermore, the higher prevalence of obesity
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Figure 5: Funnel plot for two diagnostic methods (IDF and ATP III).
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in HICs may account for this discrepancy. The current find-
ings are in line with the findings of previous reviews which
reported that the prevalence of MetS in the pediatric popula-
tion ranged from 1.2 to 22.6% in [138] and from 0 to 19.2% in
[16]. The median prevalence of MetS in the whole world was
3.3% in 2007 to 2009, which is lower than all the pooled esti-
mates in this meta-analysis [16]. This indicates that the prev-
alence of MetS is on the rise in the developed world. Besides,
the present findings are higher than the findings of a meta-
analysis in China, where 1.8% (IDF) and 2.6% (ATP III) of
the children and adolescents had MetS [139]. The findings
of the recent systematic review also revealed that the preva-
lence of MetS in the pediatric population ranged from 0.3
to 26.4%, with the lower prevalence recorded in the IDF
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17BioMed Research International
criteria (0.3-9.5%). But, the prevalence was relatively higher
in the de Ferranti et al. criteria (4-26.4%) [140]. Thus, the
current findings are in line with the findings in this study.
However, the meta-analyses results of the current study are
higher than most of the previous findings, which depict that
MetS is having an upsurge primarily in the developed world,
and it is supported by the findings of the previous reviews [9,
141, 142]. In general, the pooled prevalence of MetS among
the obese population is higher in HICs as compared to the
low- and middle-income countries, but comparable with
the general population [143].
In this study, the pooled prevalence of the components of
MetS was also computed using different diagnostic criteria.
Abdominal obesity was the most prevalent component of
MetS in the overweight and obese population ranging from
65.62% in the IDF criteria to 79.81% in the ATP III criteria.
On the other hand, a high level of FG level was the most
infrequent component of MetS in the overweight and obese
population. The pooled prevalence ranges from 1.61% (de
Ferranti et al.) to 15.53% (Weiss et al.). Similarly, the frequent
and infrequent components of MetS were computed in the
general population. Thus, the most prevalent components
include elevated BP (27.50%), low HDL-C (23.41%), high
TG level (19.05%), and abdominal obesity (14.42) with the
Cruz and Goran, IDF, ATP III, and WHO diagnostic
methods, respectively. However, the high FG level is the least
frequent component in the ATP III (7.16%) and WHO
(1.63%) criteria. Likewise, abdominal obesity and high TG
level were the least prevalent components in the Cruz and
Goran (10.06%) and IDF (7.10%) criteria. In general, the
prevalence of MetS amongst the general population is similar
between high-income and low-income countries, whereas the
prevalence is not the same amongst obese children in HICs
and low-income countries. The pooled prevalence of MetS in
the overweight and obese population was considerably higher
among children in HICs. The possible elucidation could be
due to a multitude of factors like consumption of unhealthy
diets such as diets low in fruit, vegetables, and grains [144,
145]. Moreover, sedentary behavior and lack of physical
exercise may also contribute to the rise of MetS in these
countries [146].
In most of the diagnostic methods, the prevalence of
MetS in males is relatively higher than that in females. The
pooled prevalence of MetS in the overweight and obese males
is 26.62% (IDF) and 24.75% (ATP III). Likewise, it is 20.18%
(IDF) and 24.97% (ATP III) among females. The pooled
prevalence of MetS in the general population was computed
in both genders using five diagnostic methods. Thus, the
pooled prevalence of MetS among males was higher than that
among females in the IDF (3.80%, 2.37%), ATP III (6.61%,
4.65%), and Cruz and Goran (5.53%, 4.22%) diagnostic cri-
teria. In contrast, the pooled prevalence of MetS among
males was lower compared to that of females in the de Ferr-
ranti et al. (16.49%, 16.76%) and WHO (2.66%, 3.03%) diag-
nostic criteria. In general, males are more highly at risk to
have MetS than females both in the original studies and
pooled estimates of most diagnostic methods. The current
findings are in line with the findings of a meta-analysis in
China which showed that males are more highly liable to
have MetS than females [139]. The possible justification for
gender disparities may be associated with a higher prevalence
of obesity in males than females. A higher prevalence of obe-
sity among male children and adolescents may be related to
excessive energy intake due to self- and family-imposed per-
ception of being underweight and underestimation of their
weight. On the other hand, females control their weight
through diet and physical activity due to a self-perception
of being overweight [147].
Moreover, the pooled prevalence of MetS in HICs was
computed in three continents (Asia, North America, and
Europe). Thus, 4.72%, 3.95%, and 2.54% of the study subjects
in Asia, North America, and Europe, respectively, are found
to have MetS in the IDF criteria. Similarly, the pooled preva-
lence of MetS in the ATP III criteria is 6.79% (North Amer-
ica), 6.32% (Asia), and 3.84% (Europe). These findings
pinpointed that MetS is considerably higher in HICs. This
could be associated with a high burden of childhood obesity
and consumption of unhealthy diets in these countries
[148, 149]. Childhood obesity is not only associated with
childhood MetS, but with MetS in adults [150].
Eventually, the number of cases was plotted against the
publication year (2003 to 2020), using five diagnostic
methods. The trend line revealed that the prevalence of MetS
has increased from 2003 to 2020 in all diagnostic criteria.
This implies that the prevalence of MetS is increasing in a
sustainable manner in the developed world.
The findings of this study may be used by program plan-
ners and policy makers to design preventive and treatment
strategies against morbidities and mortalities related to MetS.
These findings will also help researchers who intend to con-
duct original researches on multiple factors contributing to
a higher burden of MetS in those high-income countries.
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Figure 7: Time trend of metabolic syndrome among children and
adolescents in HICs from 2003 to 2020.
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and this could affect the actual prevalence of MetS in HICs.
The other limitation of this study was the exclusion of the fol-
lowing: studies written in non-English language, studies with
no full texts, and studies conducted in different study designs
and with a different study population. This could cause either
under- or overestimation of the pooled prevalence of MetS.
5. Conclusion
In conclusion, the current study revealed that the prevalence
of MetS among children and adolescents is high in high-
income countries with higher proportions among the over-
weight and obese population. The prevalence is considerably
higher in overweight and obese children of Asian countries.
Similarly, MetS in the general population of children and
adolescents is high in North America. Male children and
adolescents are also at greater risk of MetS than females. Met-
abolic syndrome was diagnosed in underweight, normal
weight, overweight, and obese children and adolescents. This
implies that MetS is a nonselective problem of children and
adolescents in high-income countries. Community-based
social and behavioral change communications need to be
designed to promote healthy eating behaviors and physical
activities. Prospective cohort studies could also help to
explore all possible risk factors of MetS and to design specific
interventions accordingly.
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